EN | RU
EN | RU

Help Support

Back

Determination of Zoledronic acid's cardiovascular safety in primary osteoporosis

Zoledronic acid Zoledronic acid
Zoledronic acid Zoledronic acid

The aim of this systematic review and meta-analysis was to investigate the cardiovascular safety profile of Zoledronic acid, a commonly used treatment for primary osteoporosis.

See All

Key take away

In primary osteoporosis-affected women, Zoledronic acid may raise the risk of atrial fibrillation and arrhythmias. However, Zoledronic acid-linked cardiovascular risk in men with osteoporosis is uncertain.

Background

The aim of this systematic review and meta-analysis was to investigate the cardiovascular safety profile of Zoledronic acid, a commonly used treatment for primary osteoporosis.

Method

The study focused on randomized controlled trials (RCTs) involving subjects suffering from osteoporosis who were administered Zoledronic acid or a placebo. The systematic search encompassed databases like ICTRP, ClinicalTrials.gov, PubMed, Chinese National Knowledge Infrastructure, Embase, Web of Science, Scopus, and Cochrane CENTRAL. Adhering to PRISMA guidelines, two investigators extracted data on study characteristics, risk of bias, and endpoints of interest.

Result

The search yielded 32,361 records. Following the exclusion of irrelevant entries, nine RCTs were incorporated. The overall risk ratio [RR] for cardiovascular events linked with Zoledronic acid in primary osteoporosis, compared with placebo, was 1.15 (95% CI 1.05-1.26, I2=12%).

But, the risk of major adverse cardiovascular events (MACE) with Zoledronic acid (RR 1.03, 95% CI 0.89-1.18, I2=21%) did not reach significance, possibly due to atrial fibrillation (RR 1.21, 95% CI 0.99-1.47, I2=0%), in contrast to the increased relative risk of arrhythmia (RR 1.30, 95% CI 1.11-1.52, I2=34%).

In summary, while the overall cardiovascular risk of Zoledronic acid for primary osteoporosis was not significant, the elevated relative risks of atrial fibrillation and arrhythmias warrant additional investigation.

Conclusion

Among women battling primary osteoporosis, Zoledronic acid escalated the risk of atrial fibrillation  and arrhythmias compared to placebo, irrespective of MACE, angina, and heart failure. Caution was advised when interpreting results for men having primary osteoporosis due to the small sample size. Zoledronic acid's cardiovascular risk in this population remained uncertain.

Source:

Seminars in Arthritis and Rheumatism

Article:

Cardiovascular safety of zoledronic acid in the treatment of primary osteoporosis: A meta-analysis and systematic review

Authors:

ShuangHua Liu et al.

Comments (0)

You want to delete this comment? Please mention comment Invalid Text Content Text Content cannot me more than 1000 Something Went Wrong Cancel Confirm Confirm Delete Hide Replies View Replies View Replies en ru ua
Try: